UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The gut microbiota and inflammatory bowel disease

Seminars in immunopathology, 2015-01, Vol.37 (1), p.47-55

2015

Volltextzugriff (PDF)

Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

Journal of gastroenterology, 2021-06, Vol.56 (6), p.489-526

2021

Volltextzugriff (PDF)

NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease

Intestinal research, 2020, 18(3), , pp.275-281

Matsuoka, Katsuyoshi

2020

Volltextzugriff (PDF)

Fecal microbiota transplantation for ulcerative colitis

Immunological medicine, 2021-03, Vol.44 (1), p.30-34

Matsuoka, Katsuyoshi

2021

Volltextzugriff (PDF)

Evidence-based clinical practice guidelines for inflammatory bowel disease

Journal of gastroenterology, 2018-03, Vol.53 (3), p.305-353

2018

Volltextzugriff (PDF)

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Journal of gastroenterology, 2021-06, Vol.56 (6), p.560-569

2021

Volltextzugriff (PDF)

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis

Digestive diseases and sciences, 2018-07, Vol.63 (7), p.1910-1919

2018

Volltextzugriff (PDF)

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

Journal of gastroenterology, 2013-01, Vol.48 (1), p.31-72

2013

Volltextzugriff (PDF)

A Single Strain of Clostridium butyricum Induces Intestinal IL-10-Producing Macrophages to Suppress Acute Experimental Colitis in Mice

Cell host & microbe, 2013-06, Vol.13 (6), p.711-722

2013

Volltextzugriff (PDF)

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis

Scientific reports, 2021-08, Vol.11 (1), p.16440-16440, Article 16440

2021

Volltextzugriff (PDF)

A Single Species of Clostridium Subcluster XIVa Decreased in Ulcerative Colitis Patients

Inflammatory bowel diseases, 2016-12, Vol.22 (12), p.2802-2810

2016

Volltextzugriff (PDF)

Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis

Journal of gastroenterology, 2021-09, Vol.56 (9), p.843-855

2021

Volltextzugriff (PDF)

S858 Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S635-S635

2023

Volltextzugriff (PDF)

Immune aspects of the pathogenesis of inflammatory bowel disease

Pharmacology & therapeutics (Oxford), 2013-03, Vol.137 (3), p.283-297

2013

Volltextzugriff (PDF)

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia

Journal of gastroenterology and hepatology, 2021-03, Vol.36 (3), p.637-645

2021

Volltextzugriff (PDF)

Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis

Scientific reports, 2024-02, Vol.14 (1), p.4386-4386, Article 4386

2024

Volltextzugriff (PDF)

Endoscopic morphologic features of ulcerative colitis–associated dysplasia classified according to the SCENIC consensus statement

Gastrointestinal endoscopy, 2017-03, Vol.85 (3), p.639-646.e2

2017

Volltextzugriff (PDF)

S755 Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e535-e535

2022

Volltextzugriff (PDF)

S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e558-e558

2022

Volltextzugriff (PDF)

Activated hepatic stellate cells mediate the differentiation of macrophages

Hepatology research, 2013-06, Vol.43 (6), p.658-669

2013

Volltextzugriff (PDF)

Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis

Journal of Crohn's and colitis, 2017-01, Vol.11 (1), p.84-91

2017

Volltextzugriff (PDF)

Glycolytic pathway affects differentiation of human monocytes to regulatory macrophages

Immunology letters, 2016-08, Vol.176, p.18-27

2016

Volltextzugriff (PDF)

Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study

BMJ open, 2022-05, Vol.12 (5), p.e060081-e060081

2022

Volltextzugriff (PDF)

S759 Efficacy and Safety of Mirikizumab in Patients With Ulcerative Colitis: 104-Week Results From a Phase 2 Randomized Controlled Trial

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S350-S351

2021

Volltextzugriff (PDF)

Biologic treatment of Japanese patients with inflammatory bowel disease

BMC gastroenterology, 2018-11, Vol.18 (1), p.160-160, Article 160

2018

Volltextzugriff (PDF)

1 – 25 von 337

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(294)
Mit Volltextzugriff
(304)

Publikationsform

Artikel
(336)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

The gut microbiota and inflammatory bowel disease

Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease

Fecal microbiota transplantation for ulcerative colitis

Evidence-based clinical practice guidelines for inflammatory bowel disease

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan

A Single Strain of Clostridium butyricum Induces Intestinal IL-10-Producing Macrophages to Suppress Acute Experimental Colitis in Mice

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis

A Single Species of Clostridium Subcluster XIVa Decreased in Ulcerative Colitis Patients

Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis

S858 Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy

Immune aspects of the pathogenesis of inflammatory bowel disease

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia

Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis

Endoscopic morphologic features of ulcerative colitis–associated dysplasia classified according to the SCENIC consensus statement

S755 Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial

S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial

Activated hepatic stellate cells mediate the differentiation of macrophages

Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis

Glycolytic pathway affects differentiation of human monocytes to regulatory macrophages

Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study

S759 Efficacy and Safety of Mirikizumab in Patients With Ulcerative Colitis: 104-Week Results From a Phase 2 Randomized Controlled Trial

Biologic treatment of Japanese patients with inflammatory bowel disease

Suchergebnisse filtern